The mRNA Cancer Vaccine: The Dawn of Personalised Oncology
The Trial That Changed the Field

The Phase 3 INTerpath-001 trial enrolled 1,137 patients with completely resected stage IIB-IV melanoma, a form of skin cancer with a substantial risk of returning after surgery. Participants received Merck’s immunotherapy Keytruda, either alone or alongside the personalised mRNA treatment.
The combination met its primary endpoint of recurrence-free survival. It also met a key secondary endpoint, distant metastasis-free survival—meaning patients receiving the personalised vaccine were significantly more likely to remain free of cancer spreading to distant organs.
That matters because surgery can remove everything doctors can see while leaving microscopic cancer cells behind. Those cells can eventually seed a new tumour months or years later. The vaccine is designed to give the immune system a persistent set of targets for finding those hidden remnants.
The Phase 3 success builds on striking earlier evidence. In the previous mid-stage study, five-year follow-up showed that the combination reduced the risk of recurrence or death by 49% compared with Keytruda alone. The risk of distant metastasis or death was reduced by 59%.
The new result takes that concept into a completely different category. A personalised cancer vaccine has now demonstrated its value in a large, randomised Phase 3 study.